Rapid Abstract Session A: Cancers of the Esophagus and Stomach
Marcia Cruz-Correa, MD, PhD—Chair
Abstract 5: Safety and efficacy of durvalumab following trimodality therapy for locally advanced esophageal and GEJ adenocarcinoma: Early efficacy results from Big Ten Cancer Research Consortium study.
First Author: Hirva Mamdani, MD
CONCLUSION:
Clinical trial information: NCT02639065
Abstract 6: FOLFOX versus POF (Paclitaxel plus FOLFOX) versus IP PAC (Intraperitoneal Paclitaxel plus FOLFOX) as a first-line treatment in advanced gastric cancer (AGC): A multicenter, randomized phase II trial, FNF-004 trial.
First Author: Rongbo Lin
CONCLUSION: Both POF and IP PAC improved survival compared to FOLFOX. Only POF, not IP PAC, improved response rate compared to FOLFOX. Addition with paclitaxel intravenously or intraperitoneally does not increase toxicity significantly. Clinical trial information: NCT02845908
Abstract 7: Parallel-group controlled trial of esophagectomy versus chemoradiotherapy in patients with clinical stage I esophageal carcinoma (JCOG0502).
First Author: Ken Kato, MD, PhD
CONCLUSION:
Clinical trial information: UMIN000000551
Abstract 8: Evaluation of efficacy of nivolumab by baseline factors from ATTRACTION-2.
First Author: Yoon-Koo Kang, MD, PhD
CONCLUSION:
Clinical trial information: NCT02267343